10x Genomics (NASDAQ:TXG) reported quarterly earnings results on February 12, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.13, missing the consensus estimate of $-0.10 by $0.03 per share. Revenue came in at $166.0M, beating the estimate of $159.1M.
10x Genomics's stock moved following the earnings release. The stock currently trades at $19.76 with a market capitalization of $2.0B.